Pharmacotherapy of end-stage renal disease
- 17 February 2010
- journal article
- review article
- Published by Informa Healthcare in Expert Opinion on Pharmacotherapy
- Vol. 11 (4), 597-613
- https://doi.org/10.1517/14656560903544494
Abstract
The incidence and prevalence of end-stage renal disease (ESRD) requiring renal replacement therapy (RRT) continues to grow worldwide. ESRD causes significant morbidity and mortality and has enormous financial and personal costs.Major electronic databases (including the Cochrane Library, MEDLINE and EMBASE) were searched from 1989 to September 2009 to summarize current pharmacotherapy of ESRD-associated complications in adults receiving maintenance dialysis (hemodialysis or continuous ambulatory peritoneal dialysis). Current guidelines for the treatment of ESRD (e.g., NKF-K/DOQI, KDIGO, and the ERA-EDTA's European Renal Best Practice Guidelines) were included.Commonly used pharmacological treatment strategies for chronic arterial hypertension, anemia, iron management, dyslipidemia, hyperglycemia, and for disturbances of bone and mineral metabolism, including hyperphosphatemia and secondary hyperparathyroidism in ESRD, are presented. In addition, the reader will learn that nonadherence to oral medication in ESRD can contribute significantly to excess morbidity and mortality of the dialysis population.Improvements in pharmacotherapy of ESRD may be at least in part counteracted by continuously increasing age and comorbid disease of the dialysis population. Individualized and tailor-made pharmacological management of the ESRD patient remains a challenge for the future.Keywords
This publication has 92 references indexed in Scilit:
- Pill Burden, Adherence, Hyperphosphatemia, and Quality of Life in Maintenance Dialysis PatientsClinical Journal of the American Society of Nephrology, 2009
- Rosuvastatin and Cardiovascular Events in Patients Undergoing HemodialysisNew England Journal of Medicine, 2009
- Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and meta-analysis of randomised controlled trialsThe Lancet, 2009
- Erythropoietin, Iron Depletion, and Relative Thrombocytosis: A Possible Explanation for Hemoglobin-Survival Paradox in HemodialysisAmerican Journal of Kidney Diseases, 2008
- Ferumoxytol for Treating Iron Deficiency Anemia in CKDJournal of the American Society of Nephrology, 2008
- Epoetin‐associated pure red cell aplasia: past, present, and future considerationsTransfusion, 2008
- Cognitive Impairment in the Aging Dialysis and Chronic Kidney Disease Populations: An Occult BurdenAdvances in Chronic Kidney Disease, 2008
- A systematic review of the prevalence and determinants of nonadherence to phosphate binding medication in patients with end-stage renal diseaseBMC Nephrology, 2008
- The challenge of biosimilarsAnnals Of Oncology, 2007
- Parenteral iron nephrotoxicity: Potential mechanisms and consequences1Kidney International, 2004